The historical rank and industry rank for Vistagen Therapeutics's Gross Margin % or its related term are showing as below:
VTGN's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.94 * Ranked among companies with meaningful Gross Margin % only.
Vistagen Therapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Vistagen Therapeutics was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Vistagen Therapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Vistagen Therapeutics Gross Margin % Related Terms
Vistagen Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Vistagen Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VTGN vs PLUR, PTN, CLRB: Gross Margin % Comparison
For the Biotechnology subindustry, Vistagen Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistagen Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Vistagen Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Vistagen Therapeutics (VTGN) has a Gross Margin % of 0.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Vistagen Therapeutics and its competitors. According to the industry distribution chart, Vistagen Therapeutics ranks #999999 out of 738 companies in the Biotechnology industry.
Is Vistagen Therapeutics' Gross Margin % too high?
Vistagen Therapeutics' current Gross Margin % is 0.00%. Based on the distribution chart, Vistagen Therapeutics ranks #999999 out of 738 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vistagen Therapeutics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' Gross Margin % compare to PLUR and PTN?
According to the Biotechnology industry distribution chart, Vistagen Therapeutics ranks #999999 out of 738 companies for Gross Margin %. This places Vistagen Therapeutics in the lower half of its industry. The industry median Gross Margin % is 60.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Vistagen Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistagen Therapeutics's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vistagen Therapeutics (VTGN) is currently considered Possible Value Trap. The stock's GF Value™ is $2.20, compared to a current price of $0.67 — trading 69.7% below its estimated fair value. The current Gross Margin % is 0.00%. Vistagen Therapeutics' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Vistagen Therapeutics (VTGN), the current Gross Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistagen Therapeutics (VTGN) Overvalued in 2026?
Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued.
The current stock price of $0.67 is trading 69.7% below its estimated GF Value™ of $2.20.
GuruFocus considers Vistagen Therapeutics to be Possible Value Trap.
Key valuation signals for VTGN:
Gross Margin %: 0.00%
GF Value™: $2.20 vs. price of $0.67 (69.7% below fair value)
No single metric tells the full story. See the VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
40GF Score
Get the complete analysis for VTGN
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VTGN has been successfully added to your 
